The Clinical Value of PET with Amino Acid Tracers for Gliomas WHO Grade II

Abstract EN

The clinical management of adults with low-grade gliomas (LGGs) remains a challenge.

There is no curative treatment, and management of individual patients is a matter of deciding optimal timing as well as right treatment modality.

In addition to conventional imaging techniques, positron emission tomography (PET) with amino acid tracers can facilitate diagnostic and therapeutic procedures.

In this paper, the clinical applications of PET with amino acid tracers 11C-methyl-L-methionine (MET) and 18F-fluoro-ethyl-L-tyrosine (FET) for patients with LGG are summarized.

We also discuss the value of PET for the long-term followup of this patient group.

Monitoring metabolic activity by PET in individual patients during course of disease will provide insight in the biological behavior and evolution of these tumors.

As such, spatial changes in tumor activity over time, including shifts of hot-spot regions within the tumor, may reflect intratumoral heterogeneity and correlate to clinical parameters.